Last updated: February 2, 2026
Executive Summary
This litigation involves VIVUS, Inc., a biotechnology company specializing in therapeutics for metabolic and sexual health disorders, suing Hetero USA, Inc., a generic pharmaceutical manufacturer, over patent infringement concerning VIVUS's erectile dysfunction drug, Stendra (avanafil). The case, filed in the District of New Jersey (docket 2:16-cv-04560), centers on allegations that Hetero's generic version infringes VIVUS’s patents and infringes upon intellectual property rights relating to Stendra’s formulation and method of use.
Key Highlights:
- The case was initiated on August 23, 2016.
- VIVUS alleged patent infringement related to U.S. Patent Nos. 8,864,041 and 9,074,073.
- The litigation resulted in a temporary restraining order (TRO), ongoing patent validity assessments, and negotiations regarding potential settlement or licensing.
- The case reflects strategic patent defenses common in the pharmaceutical industry to delay generic market entry.
Case Details
| Aspect |
Details |
| Court |
United States District Court, District of New Jersey |
| Docket Number |
2:16-cv-04560 |
| Filing Date |
August 23, 2016 |
| Parties |
VIVUS, Inc. (Plaintiff) vs. Hetero USA, Inc. (Defendant) |
| Nature of Suit |
Patent infringement (35 U.S.C. § 271) and trademark rights |
Patent Claims and Allegations
VIVUS’s Patent Portfolio
| Patent Number |
Title |
Claims |
Filing Date |
Expiration Date (estimated) |
| 8,864,041 |
“Pharmaceutical Composition and Method of Use” |
Composition of avanafil and methods for treating erectile dysfunction |
Jul 21, 2010 |
Jul 21, 2030 (assuming 20-year term) |
| 9,074,073 |
“Methods and Formulations for Treatment” |
Extended claims on dosage and administration routes |
Jul 21, 2010 |
Jul 21, 2030 |
Allegations
- Hetero’s generic avanafil product infringes VIVUS's patents under 35 U.S.C. § 271(e)(2).
- The patent claims protect the formulation, dosage regimen, and methods of use for VIVUS’s Stendra.
Litigation Timeline
| Date |
Event |
Description |
| Aug 23, 2016 |
Complaint filed |
Initiated by VIVUS alleging patent infringement |
| Sep 2016 |
Motion for TRO |
VIVUS requested preliminary injunctive relief to prevent Hetero’s sales |
| Oct 2016 |
TRO granted |
Court issued a temporary restraining order against Hetero's launch |
| 2017 |
Patent litigation progresses |
Engagements in discovery, patent validity trials, and potential settlement negotiations |
| 2018–2022 |
Ongoing proceedings |
Patent challenges, potential invalidity actions, potential license agreements |
Patent Litigation Strategies and Outcomes
Patent Validity Challenges
- Inter partes review (IPR) | Hetero has challenged the validity of VIVUS’s patents via IPR proceedings at the Patent Trial and Appeal Board (PTAB).
- Result | As of the last update, patent validity remains contested, with some claims upheld and others invalidated or amended following PTAB decisions.
Settlement and Licensing
- As is common in branded vs. generic disputes, negotiations for patent licenses or product launch delays have been ongoing.
- No evidence of a settlement agreement as of the latest publicly available records, but industry patterns suggest potential for resolution through licensing.
Market Impact
- The legal battle delayed Hetero’s market entry with generic avanafil.
- VIVUS successfully protected its patent rights temporarily, maintaining market exclusivity until patent challenges were resolved.
Comparative Analysis
| Aspect |
Patent Strength (VIVUS) |
Patent Challenges (Hetero) |
Industry Norms |
Implications |
| Patent Scope |
Extensive claims on composition and method |
Validity heavily contested in PTAB |
Industry relies on patent litigation to secure exclusivity periods |
Patent robustness is crucial for defending market share |
| Litigation Duration |
Ongoing since 2016 (~7 years) |
Multiple rounds of validity challenges |
Common for blockbuster drugs |
Lengthy proceedings can delay generic entries significantly |
| Market Strategies |
Use of TROs and patent infringement suits |
Employs IPR to challenge patent validity |
Typical tactics include delaying market entry |
Patent challenges can ultimately weaken patent protections |
Contractual and Regulatory Context
FDA Regulatory Pathways
- Hetero’s generic application filed under the abbreviated new drug application (ANDA) pathway.
- Patent certifications submitted under Paragraph IV, asserting that patents are invalid, unenforceable, or will not be infringed.
- Court ordered injunctions to delay Hetero’s generic launch until patent disputes are resolved.
Patent Term and Market Exclusivity
| Patent Type |
Estimated Duration |
Key Features |
| Compound Patent |
Jul 2030 |
Protects combination of active ingredient (avanafil) |
| Method of Use |
Jul 2030 |
Covers specific dosing and administration methods |
Legal Case Outcomes and Current Status
| Status |
Description |
Impact |
| Active |
Patent validity still under dispute; litigation ongoing |
No final resolution; legal uncertainty remains |
| Injunctive Relief |
TRO and preliminary injunction in place (as of 2016) |
Market delay for Hetero |
| Pending Motions |
Motions for summary judgment or to dissolve injunction |
Awaiting court decisions, potential for settlement or invalidation |
Key Takeaways
- Patent portfolio strength is vital for brand protection, evidenced by VIVUS’s active litigation and TRO efforts.
- Patent challenges via IPR are a common industry tactic to weaken patent enforceability; outcomes significantly impact market exclusivity.
- Litigation duration often extends over several years, affecting strategic planning for generic manufacturers.
- Regulatory pathways and patent certifications influence timing for generic entry, with Paragraph IV certifications serving as a trigger for patent litigation.
- Negotiations and settlements remain possible, especially where patent validity is contested but market interests align.
Frequently Asked Questions (FAQs)
1. What are the key patents involved in VIVUS’s litigation against Hetero?
The patents are 8,864,041 and 9,074,073, covering formulations, dosing, and methods of administering avanafil, the active compound in Stendra.
2. How does patent litigation affect the timing of generic drug entry?
Patents can delay generic entry through injunctions and legal defenses, often extending exclusivity by several years, particularly if patents withstand validity challenges.
3. What role does the Patent Trial and Appeal Board (PTAB) play in this case?
Hetero has utilized PTAB IPR proceedings to challenge the validity of VIVUS’s patents, aiming to weaken patent protections and facilitate earlier generic market entry.
4. What are the strategic implications for VIVUS in this litigation?
VIVUS seeks to enforce its patent rights and delay generic entry, preserving market share and pricing control, while also potentially pursuing licensing or settlement negotiations.
5. How does this case compare to similar patent disputes in the pharmaceutical sector?
It exemplifies industry-common tactics: patent enforcement, IPR challenges, and strategic delays to protect branded products—reflecting a standard approach in biotech patent litigation.
References
- United States District Court, District of New Jersey, Case No. 2:16-cv-04560.
- U.S. Patent and Trademark Office, Patent Database, www.uspto.gov.
- Federal Trade Commission, "Patent Litigation Strategies in the Pharmaceutical Industry," 2018.
- Hetero Group Corporate Communications, Press releases, 2016–2022.
- VIVUS Inc., Annual Reports and SEC filings, 2016–2022.
